Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Stephan D. Voss"'
Autor:
Brenda J. Weigel, Keith D. Wilner, David Hall, Charles G. Minard, Jennifer Foster, Peter C. Adamson, Stacey L. Berg, Elizabeth Fox, Susan M. Blaney, Stephan D. Voss, Yael P. Mosse, Frank M. Balis
Publikováno v:
Clinical Cancer Research. 27:3543-3548
Purpose: Anaplastic lymphoma kinase (ALK) aberrations are a promising target for patients with neuroblastoma. We assessed the activity of first-generation ALK inhibitor crizotinib in patients with no known curative treatments and whose tumors harbore
Autor:
Steven G. DuBois, Stephan A. Grupp, John J. Doski, Daphne A. Haas-Kogan, Julie R. Park, Lisa Diller, Geetika Khanna, Steve Braunstein, Susan G. Kreissman, Wendy B. London, Stephan D. Voss, Arlene Naranjo, Kevin X. Liu, Fan F Zhang, James D. Geiger
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 38, iss 24
J Clin Oncol
J Clin Oncol
PURPOSE A primary objective of the Children’s Oncology Group (COG) ANBL0532 phase III study was to assess the effect of increasing local dose of radiation to a residual primary tumor on the cumulative incidence of local progression (CILP) in patien
Autor:
Stacey L. Berg, Kara L. Davis, Brenda J. Weigel, Charles G. Minard, Crystal L. Mackall, Elizabeth Fox, Rachel A. Kudgus, Stephan D. Voss, Melinda S. Merchant, Joel M. Reid, Xiaowei Liu
Publikováno v:
Lancet Oncol
Summary Background Immune checkpoint inhibitors targeting PD-1 have shown clinical benefit in adults with cancer, but data on these drugs in children are scarce. We did a phase 1–2 study of nivolumab, a PD-1 blocking monoclonal antibody, to determi
Autor:
Elizabeth Fox, Sharmistha Pal, Rachel A. Kudgus, Kristina A. Cole, Stephan D. Voss, Brenda J. Weigel, Daphne A. Haas-Kogan, Bruce R. Pawel, Stacey L. Berg, John M. Maris, Xiaowei Liu, Joel M. Reid, Charles G. Minard, Heba Ijaz
Publikováno v:
Clinical Cancer Research. 26:1213-1219
Purpose: Adavosertib (AZD1775), an inhibitor of WEE1 kinase, potentiates replicative stress induced by oncogenes or chemotherapy. Antitumor activity of adavosertib has been demonstrated in preclinical models of pediatric cancer. This phase I trial wa
Autor:
Ronan Sugrue, A. Lindsay Frazier, Marc R. Laufer, Brynn E. Marks, Laurie E. Cohen, Wallace Bourgeois, Catherine M. Gordon, Stephan D. Voss
Publikováno v:
Journal of the Endocrine Society
Introduction GNAS mutations have been reported in both McCune-Albright syndrome (MAS) and juvenile granulosa cell tumors (JGCT) but have never been reported simultaneously in the same patient. Case Presentation A 15-year-old girl developed secondary
Autor:
Peter J. Houghton, Mark Krailo, Stephanie L. Safgren, Malcolm A. Smith, Hernan Carol, Yael P. Mosse, Richard B. Lock, Brenda J. Weigel, Donald A. Barkauskas, David T. Teachey, Joel M. Reid, David Hall, Elizabeth Fox, Stacey L. Berg, Stephan D. Voss, Susan M. Blaney
Publikováno v:
Clinical Cancer Research. 25:3229-3238
Purpose: Aurora A kinase (AAK) plays an integral role in mitotic entry, DNA damage checkpoint recovery, and centrosome and spindle maturation. Alisertib (MLN8237) is a potent and selective AAK inhibitor. In pediatric preclinical models, antitumor act
Autor:
Neha Kwatra, Rachel Rosen, Thomas Ng, Niharika Putta, Frederic H. Fahey, Stephan D. Voss, Laura A. Drubach, Samuel Nurko, Alejandro Flores
Publikováno v:
The American journal of gastroenterology. 115(11)
Introduction Adult standards for gastric emptying scintigraphy, including the type of meal and range of normative values for percent gastric emptying, are routinely used in pediatric practice, but to date have not been validated. The purpose of this
Autor:
Kathleen M. McCarten, Christine Mauz‐Koerholz, Angela Punnett, Jamie E. Flerlage, Kara M. Kelly, Sue C. Kaste, Stephan D. Voss, Pedro A. de Alarcon, Bradford S. Hoppe, Jennifer Seelisch, Monika L. Metzger, Dietrich Stroevesandt, Lars Kurch, Lianna J. Marks
Publikováno v:
Paediatrics Publications
Waldeyer's ring (WR) involvement in pediatric Hodgkin lymphoma (HL) is extremely rare and criteria for determining involvement and response to treatment are unclear. The international Staging, Evaluation, and Response Criteria Harmonization for Child
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44bc786267359e26150fef7246465a6e
https://ir.lib.uwo.ca/paedpub/425
https://ir.lib.uwo.ca/paedpub/425
Autor:
Peter C. Adamson, Emily Greengard, Charles G. Minard, Stephan D. Voss, Elizabeth Fox, Brenda J. Weigel, Keith D. Wilner, Joel M. Reid, Xiaowei Liu, Yael P. Mosse, Susan M. Blaney, Frank M. Balis
Publikováno v:
Cancer Chemother Pharmacol
This phase 1 study aimed to determine the safety, tolerability and recommended phase 2 dose (RP2D) of crizotinib in combination with cytotoxic chemotherapy for children with refractory solid tumors and ALCL. Pediatric patients with treatment refracto
Autor:
Auke Beishuizen, Monika L. Metzger, Lars Kurch, Steve Y. Cho, Jamie E. Flerlage, Christine Mauz‐Koerholz, Stephan D. Voss, Melanie M. Hagleitner, Regine Kluge, Kara M. Kelly
Publikováno v:
Pediatric Blood & Cancer. 67
Hepatic involvement in Hodgkin lymphoma (HL) is uncommon (∼5% of patients) but always implies stage IV disease. Accurate staging is mandatory for making the appropriate risk assignment and treatment decisions. The Staging Evaluation and Response Cr